Study Comparing Azenosertib to Chemotherapy for Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancers with Cyclin E1 Protein

Inclusion Criteria

• Women aged 18 or older.
• Diagnosed with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
• Cancer must be measurable by scans.
• Good overall health with a performance status score of 0 or 1.
• Cancer must show Cyclin E1 protein.
• Must have cancer that is resistant to platinum-based treatments.
• Allowed 1 to 3 previous treatments (or up to 4 if previously treated with mirvetuximab).
• Must have had prior treatment with bevacizumab, PARP inhibitors (if applicable), and mirvetuximab (if applicable).
• Must have adequate blood and organ function.

Exclusion Criteria

• History of another cancer in the past 2 years, unless treated and disease-free.
• Cancer that did not respond to initial platinum-based treatment.
• Previous treatment with azenosertib or similar drugs.
• Serious medical conditions, including:
  • Unstable brain cancer requiring immediate treatment.
  • Severe kidney issues or need for a catheter.
  • Significant digestive problems affecting medication intake.
  • Recent or recurrent bowel obstruction.
  • Active, uncontrolled infections.
  • Heart failure.
  • Any condition that increases risk or affects study results.
• Recent hospitalization, major surgery, or cancer treatments.
• Use of certain medications or supplements that cannot be stopped.
• Previous extensive radiation therapy.
• Unresolved side effects from past treatments.
• Immunocompromised or HIV-positive on certain therapies.
• Active hepatitis B or C infection.
• Judged unsuitable for the study by the doctor.